Advertisement

Topics

Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates

04:04 EDT 31 Jul 2017 | Cancer Networks

Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study.

Original Article: Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates

NEXT ARTICLE

More From BioPortfolio on "Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates"

Quick Search
Advertisement